Bifidobacterium in the treatment of inflammatory disease

Details Bifidobacterium in the treatment of inflammatory disease Bifidobacterium in the treatment of inflammatory disease

2007-03-27

2007-03-27

Afremova, Vera (Department: 1657)

Chemistry: molecular biology and microbiology

Micro-organism, per se ; compositions thereof; proces of...

Bacteria or actinomycetales; media therefor

C435S252900, C435S252400, C435S822000, C435S853000, C424S093400, C424S093450, C424S093300

Reexamination Certificate

active

10783020

ABSTRACT:
A strain ofBifidobacteriumisolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.

REFERENCES:
patent: 4347240 (1982-08-01), Mutai et al.
patent: 4435389 (1984-03-01), Mutai et al.
patent: 5032399 (1991-07-01), Gorbach et al.
patent: 5443826 (1995-08-01), Borody
patent: 5711977 (1998-01-01), Yang et al.
patent: 5834423 (1998-11-01), Koketsu et al.
patent: 5922375 (1999-07-01), Luchansky et al.
patent: 6025008 (2000-02-01), Akahoshi et al.
patent: 6077504 (2000-06-01), Cavaliere ved. Vesley et al.
patent: 6132710 (2000-10-01), Panigraphi et al.
patent: 6368591 (2002-04-01), Chen et al.
patent: 6645530 (2003-11-01), Borody
patent: 2002/0006432 (2002-01-01), Collins et al.
patent: 2003/0170217 (2003-09-01), Collins et al.
patent: 2003/0215467 (2003-11-01), Collins et al.
patent: 2005/0214272 (2005-09-01), Collins et al.
patent: 2006/0002908 (2006-01-01), Collins et al.
patent: 0 508 701 (1996-07-01), None
patent: 0 904 784 (1999-03-01), None
patent: 0 384 319 (1999-04-01), None
patent: 1 312 667 (2003-05-01), None
patent: 1 503 094 (1978-03-01), None
patent: 9241173 (1997-09-01), None
patent: 2 091 075 (1997-09-01), None
patent: 2 109 054 (1998-04-01), None
patent: WO 89/05849 (1989-06-01), None
patent: WO 90/01335 (1990-02-01), None
patent: WO 90/09398 (1990-08-01), None
patent: WO 97/35596 (1997-10-01), None
patent: WO 98/00035 (1998-01-01), None
patent: WO 98/35014 (1998-08-01), None
patent: WO 98/35014 (1998-08-01), None
patent: WO 99/51631 (1999-10-01), None
patent: WO 99/62348 (1999-12-01), None
patent: WO 01/37865 (2001-05-01), None
Kim et al. Korean Journal of Dairy Science, (1998) vol. 20, Mo. 3, pp. 191-204.
Yildirim et al., “Characterization and antimicrobial spectrum of bifidocin B, a bacteriocin produced by Bifidobacterium bifidum NCFB 1454,” J Food Prot, 61(1):47-51, (1998), Abstract Only.
Adachi, Susumu, “Lactic Acid Bacteria and the Control of Tumours,” The Lactic Acid Bacteria, 1:233-261, (1992).
Anand et al., “Antibacterial Activity Associated with Bifidobacterium bifidum—II,” Cult. Dairy Prod, pp. 21-23, (1985). (Attached copy is missing 1 page).
Arai et al., “Cytokines: Coordinators of Immune and Inflammatory Responses,” Annual Rev. Biochem., 59:783-836, (1990).
Aranda et al., “Analysis of Intestinal Lymphocytes in Mouse Colitis Mediated by Transfer of CD4+, CD45RBhighT Cells to SCID Recipients1,” Jour. of Immunology, 158(7):3464-3473, (1997).
Arihara, et al., “Salivacin 140, a novel bacteriocin fromLactobacillus salivariussubsp. salicinius T140 active against pathogenic bacteria,” Letters in Applied Microbiology, 22:420-424, (1996).
Bachwich, et al., “Tumor Necrosis Factor Stimulates Interleukin-1 and Prostaglandin E2Production in Resting Macrophages,” Biochemical and Biophysical Res. Comm., 136(1):94-101, (1986).
Blum et al., “Adhesion studies for probiotics: need for validation and refinement,” Trends in Food Science & Technology, 10:405-410 (1999).
Bouhnik et al., “Effects of Bifidobacterium sp fermented milk ingested with or without inulin on colonic bifidobacteria and enzymatic activities in healthy humans,” Eur. Jour. Clin. Nut., 50:269-273, (1996).
Bouhnik et al., “Survie et effets chez I′homme des bactéries ingérées dans less laits fermentés,” LAIT, 73:241-247, (1993).
Brandtzaeg et al., “Immunopathology of human inflammatory bowel disease,” Springer Semin Immunopath, 18:555-589, (1997).
Brink et al., “Antimicrobial activity of lactobacilli: preliminary characteristization and optimization of production of acidocin B a novel bacteriocin produced byLactobacillus acidophilusM,” Jour. of Applied Bacteriology, 77:140-148, (1994).
Brzuszczak et al., “Cyclic AMP-dependent anion secretion in human small and large intestine,” Jour. of Gastroenterology and Hepatology, 11:804-810, (1996).
Charteris et al., “Antibiotic susceptibility of potentially probiotic Bifidobacterium isolates from the human gastrointestinal tract,” Letters in Applied Microbiology, 26:333-337, (1998).
Charteris et al., “Selective detection, enumeration and identification of potentially probiotic Lactobacillus and Bifidobacterium species in mixed bacterial populations,” Int. Jour. of Food Microbiology, 35:1-27, (1997).
Charteris, et al., “Antibiotic Susceptibility of Potentially Probiotic Lactobacillus Species,” Jour. Food Protection, 61(12):1636-1643, (1998).
Charteris, et al., “Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract,” Jour. of Applied Microbiology, 84:759-768, (1998).
Chauvière et al., “Adhesion of humanLactobacillus acidophilusstrain LB to human eterocyte-like Caco-2 cells,” Journal of General Microbiology, 138:1689-1696, (1992).
Chevalier et al., “Detection of Bifidobacterium species by enzymatic methods,” Jour. of Appl. Bacteriology, 68:619-624, (1990).
Cicco et al., “Inducible Production of Interleukin-6 by Human Polymorphonuclear Neutrophils: Role of Granulocyte-Macrophage Colony-Stimulating Factor and Tumor Necrosis Factor-alpha,” Blood, 75(10):2049-2052, (1990).
Collins et al., “A Controlled Trial of Probiotic Treatment of IL-10 Knockout Mice,” Gastroenterology, 116(4):1 page, (1999). Abstract G2981.
Collins et al., “Demonstration of Probiotic Function in a Double Blind Placebo Controlled Clinical Trials in Adults,” Functional Food Research in Europe, pp. 40-41, (1998).
Collins et al., “Probiotics and Man—The Host Microbe Interface,” Gastroenterology, 116(4):1 page, (1999). Abstract G2982.
Collins et al., “Selection of Probiotic Strains for Human Applications,” Int. Dairy Journal, 8:487-490, (1998).
Collins, “Probiotic Lactobacilli-Towards Defining Selection and Functional Criteria,” Demonstration Fair CT96-1028, p. 27, (1996).
Collins, “Selection of Probiotic Strains and Potential Therapeutic Applications,” Book of Abstracts from Eur. Comm. Biotech and Fair Prog., p. L-2, (1995).
Collins et al., “Probiotic bacteria-interaction with the human immune system,” Int. Congress and Symp. Series 219, pp. 13-17, (1996).
Collins, J.K., “Probiotics and Inflammatory Bowel Disease: Animal Models,” Functional Food Research in Europe, p. 124, (1998).
Cong et al., “Genes, Bacteria, and T Cells: Ingredients for Inflammatory Bowel Disease,” Gastroenterology, 115:1595-1596, (1998). (Summary by Shanahan, O'Sullivan, and Collins).
Crabbe et al., “The Normal Microbial Flora as a Major Stimulus for Proliferation of Plasma Cells Synthesizing IgA in the Gut,” Int. Arch. Allergy 34:362-375, (1968).
Daly et al., “Biotechnology of lactic acid bacteria with special reference to bacteriophage resistance,” Antonie Van Leewenhoek, 70:99-110, (1996).
Darveau, Richard, “Infection, inflammation, and cancer,” Nature Biotechnology, 17:19, (1999).
Dawson et al., “18 pH, buffers, and physiological media,” Data For Biochemical Research, pp. 417-448, (1969).
Dekker et al., “Sensitive Pulsed Amperometric Detection of Free and Conjugated Bile Acids in Combination with Gradient Reversed-Phase HPLC,” Chromatographia, 31(11/12):549-553, (1991).
Dinarello et al., “New Concepts on the Pathogenesis of Fever,” Reviews of Infectious Diseases, 10(1):168-189, (1988).
Donnelly, et al., “Differential Regul

Affiliated with

Also associated with

Rating

Bifidobacterium in the treatment of inflammatory disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bifidobacterium in the treatment of inflammatory disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bifidobacterium in the treatment of inflammatory disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3749117